{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {},
    "annotation_url": {
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Lingling Xu",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
      "version": "1.0.1"
    },
    "namespace_pattern": {},
    "namespace_url": {
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
    },
    "path": "tau/kanaan2011.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cytoplasm": true,
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "perfusion of full-length WT tau monomers (2 􏰊M) (Fig. 1 A) had no effect on FAT in squid axoplasm (Fig. 2 A), while 6D and 6P tau monomers (2 􏰊M) significantly inhibited anterograde FAT when compared with WT tau monomer (Fig. 2 B, C) or buffer controls (data not shown).",
      "key": "29905b13d40672d6c74c44e87a6a84e1",
      "line": 83,
      "relation": "causesNoChange",
      "source": 12,
      "subject": {
        "modifier": "Translocation"
      },
      "target": 2
    },
    {
      "key": "b5ef526ab5a17da51fd96bb875e02aac",
      "relation": "hasVariant",
      "source": 12,
      "target": 13
    },
    {
      "key": "286eeda0d4fc7d45da3532a3c5dd1916",
      "relation": "hasVariant",
      "source": 12,
      "target": 15
    },
    {
      "key": "ed64f6f261cfc8877aa67011f6730b15",
      "relation": "hasVariant",
      "source": 12,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cytoplasm": true,
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "perfusion of full-length WT tau monomers (2 􏰊M) (Fig. 1 A) had no effect on FAT in squid axoplasm (Fig. 2 A), while 6D and 6P tau monomers (2 􏰊M) significantly inhibited anterograde FAT when compared with WT tau monomer (Fig. 2 B, C) or buffer controls (data not shown).",
      "key": "80e8a9308938bf7435153b080e745d37",
      "line": 84,
      "relation": "decreases",
      "source": 5,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mechanism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "key": "2dc06e974d055aa51e3d247ad48c8457",
      "line": 97,
      "relation": "decreases",
      "source": 5,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "As observed with Δ2–18 tau aggregates (LaPointe et al., 2009), monomeric Δ2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT.",
      "key": "bef5ca0c50da8e0a5f582033c59ed368",
      "line": 107,
      "relation": "decreases",
      "source": 5,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Neither 6D nor 6P tau (Fig. 2D) had an effect on retrograde FAT",
      "key": "cba3a7ba721b9dcf55cc2ad22338189c",
      "line": 91,
      "relation": "causesNoChange",
      "source": 5,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mechanism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "key": "7db6240f1de96bfb2a590a446f4b45ea",
      "line": 98,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 5,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mechanism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "key": "8c5ea9511be5c87b5e48ff2ea9fdec80",
      "line": 99,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 5,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cytoplasm": true,
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "perfusion of full-length WT tau monomers (2 􏰊M) (Fig. 1 A) had no effect on FAT in squid axoplasm (Fig. 2 A), while 6D and 6P tau monomers (2 􏰊M) significantly inhibited anterograde FAT when compared with WT tau monomer (Fig. 2 B, C) or buffer controls (data not shown).",
      "key": "4b87b58324bfa6d111d60203ac162c27",
      "line": 85,
      "relation": "decreases",
      "source": 6,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Neither 6D nor 6P tau (Fig. 2D) had an effect on retrograde FAT",
      "key": "5ee1fd38de5f31086b639dcc02b63899",
      "line": 92,
      "relation": "causesNoChange",
      "source": 6,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mechanism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "key": "515c36669dd28bacc3d18a75b99a44c3",
      "line": 100,
      "relation": "decreases",
      "source": 19,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an-terograde FAT by activating the PP1–GSK3 cascade.",
      "key": "0b751c2cb28d72018d43533bc8c8f3fa",
      "line": 147,
      "relation": "decreases",
      "source": 19,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mechanism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "key": "ffabf83a957d2559c409faf91ca7e7b1",
      "line": 101,
      "relation": "decreases",
      "source": 17,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Again, coperfusion of the PAD peptide with either I-2 (50 nM) (Fig. 5A) or ING-135 (100 nM) (Fig. 5B) completely prevented anterograde FAT inhibition. ",
      "key": "796fe4c0090c746dc71a2c7fde132c04",
      "line": 123,
      "relation": "decreases",
      "source": 17,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an-terograde FAT by activating the PP1–GSK3 cascade.",
      "key": "7e2b479f963fb243c6e0b8750c586a1b",
      "line": 146,
      "relation": "decreases",
      "source": 17,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "As observed with Δ2–18 tau aggregates (LaPointe et al., 2009), monomeric Δ2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT.",
      "key": "cd34fed430bbc1dbd7af96371cb379bd",
      "line": 106,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 9,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "The PAD peptide selectively inhibited anterograde FAT (Fig. 4 B, D), but not retrograde FAT (Fig. 4B,E).",
      "key": "37d385a4055772f042cabb1e568dff22",
      "line": 112,
      "relation": "decreases",
      "source": 9,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an-terograde FAT by activating the PP1–GSK3 cascade.",
      "key": "20bffe08aababbca15db73d102c47747",
      "line": 145,
      "relation": "decreases",
      "source": 9,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data indicate that disease- associated modifications and mutations in tau that increase exposure of PAD promote activation of the PP1–GSK3 pathway and inhibition of anterograde FAT.",
      "key": "48daab2f566c642bb44520157f53da10",
      "line": 174,
      "relation": "decreases",
      "source": 9,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "The PAD peptide selectively inhibited anterograde FAT (Fig. 4 B, D), but not retrograde FAT (Fig. 4B,E).",
      "key": "f3f0047fcac4e853cde2dd13d49727f7",
      "line": 113,
      "relation": "causesNoChange",
      "source": 9,
      "target": 3
    },
    {
      "key": "3b1f9989c3d471c80c5cbbe547883680",
      "relation": "partOf",
      "source": 9,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cytoplasm": true,
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "P-c-Jun was dephosphorylated to a greater extent in PAD peptide-perfused axoplasms than their scrambled peptide- perfused counterpart (Fig. 5F ), suggesting that the PAD peptide induced activation of endogenous axoplasmic phosphatases.",
      "key": "1db710c465b10b02224e517d3e9e09c9",
      "line": 129,
      "relation": "decreases",
      "source": 9,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cytoplasm": true,
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "P-c-Jun was dephosphorylated to a greater extent in PAD peptide-perfused axoplasms than their scrambled peptide- perfused counterpart (Fig. 5F ), suggesting that the PAD peptide induced activation of endogenous axoplasmic phosphatases.",
      "key": "e66dfd34aa21730f8011d85ad0cfb9ec",
      "line": 130,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 9,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cytoplasm": true,
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "A trend of elevated GSK3 activity (􏰈32%) relative to PKC activity ( p 􏰄 0.28, paired t test; n 􏰄 3) was observed for axoplasms incubated with the PAD peptide (mean 􏰄 4.9 􏰉 2.5), compared with those incubated with scrambled peptide (mean 􏰄 3.7 􏰉 1.7), which supports the results from vesicle motility assays. ",
      "key": "a1f91456bbb63e947bcb5e09a822e42a",
      "line": 137,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 9,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an-terograde FAT by activating the PP1–GSK3 cascade.",
      "key": "ec24296a871005c90063df008aacde88",
      "line": 143,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 9,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data indicate that disease- associated modifications and mutations in tau that increase exposure of PAD promote activation of the PP1–GSK3 pathway and inhibition of anterograde FAT.",
      "key": "5c10c9ba1cddae28547ee1358a5e97ce",
      "line": 172,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 9,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an-terograde FAT by activating the PP1–GSK3 cascade.",
      "key": "f48012ee9e2ad6ec190b08704fb9c5a1",
      "line": 144,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 9,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data indicate that disease- associated modifications and mutations in tau that increase exposure of PAD promote activation of the PP1–GSK3 pathway and inhibition of anterograde FAT.",
      "key": "36e75248ab25179c524f020d33c92345",
      "line": 173,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 9,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "To evaluate the relevance of these findings in human disease, we generated a novel monoclonal antibody, termed TNT1, which specifically recognizes PAD.",
      "key": "9d869608c9484a26dba0e81dce89775e",
      "line": 179,
      "relation": "association",
      "source": 9,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Again, coperfusion of the PAD peptide with either I-2 (50 nM) (Fig. 5A) or ING-135 (100 nM) (Fig. 5B) completely prevented anterograde FAT inhibition. ",
      "key": "bce7a47457b9d6a95936e622688bc27d",
      "line": 122,
      "relation": "increases",
      "source": 4,
      "target": 1
    },
    {
      "key": "e02c18327fba52b6a34136256bd4be8c",
      "relation": "partOf",
      "source": 16,
      "target": 4
    },
    {
      "key": "ab15b447e1a18ed2e0a44e04b6dcba5a",
      "relation": "hasVariant",
      "source": 10,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phosphorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "key": "f0fa63f186760ef97b288afb02c5587c",
      "line": 154,
      "relation": "decreases",
      "source": 7,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phosphorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "key": "8a9eeaee946dc97fcb4c68f6042e6de7",
      "line": 155,
      "relation": "causesNoChange",
      "source": 7,
      "target": 3
    },
    {
      "key": "d3471b0619c827625b9fc3af30ca4c7b",
      "relation": "hasVariant",
      "source": 7,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Together, these data suggest that increased PAD exposure represents an early event in AD pathogenesis and that AT8 may not be required for PAD exposure in situ.",
      "key": "14ec51f96c9c0e83b0bf7a78b779b3db",
      "line": 190,
      "relation": "causesNoChange",
      "source": 7,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phosphorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "key": "0ac2332a5276323e4f646822412776fe",
      "line": 157,
      "relation": "association",
      "source": 8,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phosphorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "key": "b588e33255013aa1d8113eeeb3412e3e",
      "line": 158,
      "relation": "association",
      "source": 8,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phosphorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "key": "a003d262834d73d56dcecf240976c078",
      "line": 157,
      "relation": "association",
      "source": 13,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phosphorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "key": "917cd1bf9ab0032ef4eea485360d7139",
      "line": 158,
      "relation": "association",
      "source": 21,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Consistent with our model, Δ144 –273 tau monomers significantly inhibited anterograde FAT (Fig. 6 B, C), while retrograde FAT remained unaffected (Fig. 6 B, D).",
      "key": "08b991c07887cf9ca3b2cbc695f41476",
      "line": 164,
      "relation": "decreases",
      "source": 15,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Consistent with our model, Δ144 –273 tau monomers significantly inhibited anterograde FAT (Fig. 6 B, C), while retrograde FAT remained unaffected (Fig. 6 B, D).",
      "key": "0aafa387321e30a84fd58af75d625603",
      "line": 165,
      "relation": "causesNoChange",
      "source": 15,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "Together, these data indicate that disease- associated modifications and mutations in tau that increase exposure of PAD promote activation of the PP1–GSK3 pathway and inhibition of anterograde FAT.",
      "key": "825f59ae06d3a6651b06417d38d29181",
      "line": 171,
      "relation": "increases",
      "source": 14,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "To evaluate the relevance of these findings in human disease, we generated a novel monoclonal antibody, termed TNT1, which specifically recognizes PAD.",
      "key": "b03c4d267f5d512ccf18dd047311b530",
      "line": 179,
      "relation": "association",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": "These data indicated that increased PAD exposure, as revealed by TNT1 immunoreactivity, occurs early in AD and remains present throughout the disease process.",
      "key": "2ffe75e59ecab79343b5fffc9c2b375d",
      "line": 184,
      "relation": "increases",
      "source": 20,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Andreadis A",
          "Binder LI",
          "Brady ST",
          "Fu Y",
          "Kanaan NM",
          "LaPointe NE",
          "Morfini GA",
          "Patterson KR",
          "Pigino GF",
          "Song Y"
        ],
        "date": "2011-07-06",
        "db": "PubMed",
        "db_id": "21734277",
        "db_name": "Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.",
        "first": "Kanaan NM",
        "journal": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "last": "Binder LI",
        "pages": "9858-68",
        "volume": "31"
      },
      "evidence": " Together, these data suggest that increased PAD exposure represents an early event in AD pathogenesis and that AT8 may not be required for PAD exposure in situ.",
      "key": "871944dc00b110e1b33e3ab59ae24421",
      "line": 189,
      "relation": "increases",
      "source": 20,
      "target": 9
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CONSO:\"Tau antibody, TNT1\")",
      "concept": {
        "name": "Tau antibody, TNT1",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "c4ef0061c52c28ceca1856943c34531e"
    },
    {
      "bel": "bp(GO:\"anterograde axonal protein transport\")",
      "concept": {
        "name": "anterograde axonal protein transport",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "35ebd956d85fb57273a53f4faf10d196"
    },
    {
      "bel": "bp(GO:\"axonal transport\")",
      "concept": {
        "name": "axonal transport",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "c9d614fb05004498d4069f216f0458c8"
    },
    {
      "bel": "bp(GO:\"retrograde axonal protein transport\")",
      "concept": {
        "name": "retrograde axonal protein transport",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "e82d8b33078be6adb0f37c60032c72db"
    },
    {
      "bel": "composite(p(CONSO:\"phosphatase-activating domain\"), p(HGNC:PPP1R2))",
      "function": "Composite",
      "id": "ed07f64747022c2929fd99dcefa1232c",
      "members": [
        {
          "bel": "p(CONSO:\"phosphatase-activating domain\")",
          "concept": {
            "name": "phosphatase-activating domain",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "badc65969c9d25b5f6552435c43c7e50"
        },
        {
          "bel": "p(HGNC:PPP1R2)",
          "concept": {
            "name": "PPP1R2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "2c1614049302f83de74144819be0dcdc"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"Tau 6D\")",
      "concept": {
        "name": "Tau 6D",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "5962545505a3a44c37e94254e0ef4097"
    },
    {
      "bel": "p(CONSO:\"Tau 6P\")",
      "concept": {
        "name": "Tau 6P",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "0ac398c0b4c6072f3ecc9c344b8c557c"
    },
    {
      "bel": "p(CONSO:\"Tau epitope, AT8\")",
      "concept": {
        "name": "Tau epitope, AT8",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "6dd17eb2a65858826878cae123da6085"
    },
    {
      "bel": "p(CONSO:\"Tau epitope, AT8\", pmod(Ph))",
      "concept": {
        "name": "Tau epitope, AT8",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "f1a52ad85377b14f082318903c8e2677",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"phosphatase-activating domain\")",
      "concept": {
        "name": "phosphatase-activating domain",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "badc65969c9d25b5f6552435c43c7e50"
    },
    {
      "bel": "p(HGNC:JUN)",
      "concept": {
        "name": "JUN",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0f80512a01fa9da3da3e442cd3289fc7"
    },
    {
      "bel": "p(HGNC:JUN, pmod(Ph))",
      "concept": {
        "name": "JUN",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "89c3455f8db6401c39e6062b0faae39a",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(CONSO:hyperphosphorylation))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0d2d8072f03dcdf148e658067d37b9cb",
      "variants": [
        {
          "concept": {
            "name": "hyperphosphorylation",
            "namespace": "CONSO"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, var(\"?\"))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "82ca363b9b9e9f7f2e880d0674096ecf",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, var(\"p.Gly144_Ser273del\"))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "aa6f9c9760f701c48c9b1074deb21959",
      "variants": [
        {
          "hgvs": "p.Gly144_Ser273del",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:PPP1R2)",
      "concept": {
        "name": "PPP1R2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2c1614049302f83de74144819be0dcdc"
    },
    {
      "bel": "p(MESH:\"Glycogen Synthase Kinase 3\")",
      "concept": {
        "name": "Glycogen Synthase Kinase 3",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "e9e397cdbd84a40d966c4a8bd6b70f6a"
    },
    {
      "bel": "p(MESH:\"Phosphoprotein Phosphatases\")",
      "concept": {
        "name": "Phosphoprotein Phosphatases",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "aebd272f6ed468060efa849046d97097"
    },
    {
      "bel": "p(MESH:\"Protein Phosphatase 1\")",
      "concept": {
        "name": "Protein Phosphatase 1",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "38ae60c1cfeb0ec480eef7bd75c79077"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "concept": {
        "name": "Alzheimer Disease",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2ae8307f5fd59056199369691367cc96"
    },
    {
      "bel": "path(MESH:Tauopathies)",
      "concept": {
        "name": "Tauopathies",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e7af59eca49dd3e30ab0fb75db41527a"
    }
  ]
}